REVIEW

Pharmacological Properties and Therapeutic Potential of Papaverine: A Comprehensive Review

Papaverinin Farmakolojik Özellikleri ve Tedavi Potansiyeli: Kapsamlı Bir Derleme

Gamze Mercan[1] Zümrüt Varol Selçuk[2]

1- Hacettepe University, Department of Nanotechnology and Nanomedicine, Ankara, Türkiye.
2- Ordu University, Department of Mathematics and Science Education, Ankara, Türkiye.

DOI:10.38175/phnx.1570322

Cite as:
Mercan G, Varol Selçuk Z. Pharmacological Properties and Therapeutic Potential of Papaverine: A Comprehensive Review. Phnx Med J. 2025;7(1):1-4.

Correspondence:
Gamze Mercan, Hacettepe University, Department of Nanotechnology and Nanomedicine, Ankara, Türkiye.

E mail: gmercn@gmail.com

Received: 19 Ekim 2024
Accepted: 10 Ocak 2025
Online Published: 06.Mart.2025

ABSTRACT

Papaverine, a prominent benzylisoquinoline alkaloid extracted from Papaver somniferum L., has long been used for its vasodilatory properties in clinical settings. Despite its structural distinction from opiate alkaloids, papaverine is known for inhibiting cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) phosphodiesterase in smooth muscle cells, leading to increased intracellular concentrations of these molecules. This mechanism contributes to the dilation of cerebral, coronary, and pulmonary arteries and enhances cerebral blood flow while reducing vascular resistance. Beyond its established use, recent research has revealed papaverine's extensive pharmacological activities, including its effects in treating erectile dysfunction, managing postoperative vasospasms, and alleviating pulmonary vasoconstriction. Furthermore, its antiviral, anti-inflammatory, cardioprotective, neuroprotective, and anticancer properties have garnered significant attention. Notably, papaverine has demonstrated potential in controlling the cytopathic effects of SARS-CoV-2, positioning it as a candidate for therapeutic development against viral infections. Despite promising findings, further research is needed to understand the full spectrum of its molecular mechanisms and to address concerns about its long-term safety and toxicity. This review aims to provide an in-depth analysis of papaverine's pharmacological actions, therapeutic applications, and the molecular pathways involved, with an emphasis on its potential as a versatile agent in modern medicine.

Keywords: *Papaverine, Papaver somniferum, vasodilator, antiviral*

ÖZET

Papaver somniferum L.'den elde edilen önemli bir benzilizokinolin alkaloidi olan papaverin, klinik ortamlarda uzun süredir vazodilatör özellikleri ile kullanılmaktadır. Opiat alkaloidlerinden yapısal olarak farklı olmasına rağmen, papaverin, düz kas hücrelerinde siklik adenozin monofosfat (cAMP) ve siklik guanozin monofosfat (cGMP) fosfodiesterazını inhibe etmesiyle bilinir. Bu mekanizma, bu moleküllerin hücre içi konsantrasyonlarının artmasına yol açar ve bu da serebral, koroner ve pulmoner arterlerin genişlemesine, serebral kan akışının artmasına ve vasküler direncin azalmasına katkı sağlar. Yerleşik kullanımının ötesinde, son araştırmalar papaverinin erektil disfonksiyon tedavisi, postoperatif vazospazmların yönetimi ve pulmoner vazokonstriksiyonun hafifletilmesi gibi kapsamlı farmakolojik aktivitelerini ortaya koymuştur. Ayrıca, antiviral, anti-inflamatuar, kardiyoprotektif, nöroprotektif ve antikanser özellikleri büyük ilgi görmektedir. Özellikle, papaverin, SARS-CoV-2'nin sitopatik etkilerinin kontrolünde potansiyel göstermiş ve viral enfeksiyonlara karşı tedavi geliştirilmesi için bir aday olarak öne çıkmıştır. Umut verici bulgulara rağmen, moleküler mekanizmalarının tam olarak anlaşılması ve uzun vadeli güvenliği ve toksisitesi konusundaki endişelerin giderilmesi için daha fazla araştırmaya ihtiyaç vardır. Bu derleme, papaverinin farmakolojik etkilerini, tedavi uygulamalarını ve ilgili moleküler yolları derinlemesine analiz etmeyi ve modern tıpta çok yönlü bir ajan olarak potansiyelini vurgulamayı amaçlamaktadır.

Anahtar Kelimeler: *Papaverin, Papaver somniferum, vazodilatör, antiviral*

INTRODUCTION

Since ancient times, medicinal plants have been a cornerstone in traditional healing practices across diverse cultures. The utilization of natural compounds derived from these plants has led to the discovery of several therapeutic agents that are still relevant in modern medicine (1). Among these bioactive compounds, alkaloids play a significant role due to their broad pharmacological properties. One particular class of alkaloids, benzylisoquinoline alkaloids, has attracted considerable scientific attention for its potential in treating a range of diseases (2). This group includes well-known compounds such as morphine and codeine, but also non-narcotic agents like papaverine (3).

Papaverine, extracted from *Papaver somniferum* (opium poppy), is distinguished by its ability to act as a vasodilator, a property that has made it valuable in the treatment of cerebral, coronary, and pulmonary artery diseases (4). Unlike its opiate counterparts, papaverine does not exert analgesic effects, but instead inhibits phosphodiesterase enzymes, specifically targeting the cAMP and cGMP pathways in smooth muscles (5). This inhibition leads to elevated intracellular levels of these cyclic nucleotides, resulting in smooth muscle relaxation and increased blood flow (6). These mechanisms have made papaverine a widely used therapeutic agent in clinical settings for treating conditions such as erectile dysfunction and postoperative vasospasms (7).

Recent research has expanded the scope of papaverine's pharmacological actions, suggesting it may hold promise

beyond its traditional uses. Studies have shown its potential in the management of pulmonary vasoconstriction, neuroprotective effects, and even anticancer properties, with mechanisms involving the modulation of mitochondrial activity and cell cycle arrest in various tumor cell lines (8,9). Additionally, papaverine has demonstrated antiviral activity, notably in the inhibition of SARS-CoV-2 cytopathic effects, positioning it as a candidate for further exploration in viral therapeutics (10).

Despite these promising findings, papaverine's therapeutic potential remains underexplored in many areas, and comprehensive studies are needed to understand its full range of molecular actions, pharmacokinetics, and long-term safety profiles (11). This review aims to summarize and critically analyze the current literature on papaverine's pharmacological properties, with a focus on its emerging roles in various therapeutic contexts. By doing so, we hope to provide a foundation for future research and clinical applications of this versatile alkaloid.

PHYTOCHEMICAL PROFILE OF PAPAVERINE

Overview of Papaverine's Chemical Structure and Biosynthesis

Papaverine is a benzylisoquinoline alkaloid characterized by its unique chemical structure, distinct from other opiate alkaloids such as morphine and codeine. Its molecular structure, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, comprises a fully aromatic isoquinoline core with four methoxy groups attached to the benzyl moiety (1). This structure underlies its non-narcotic properties, unlike the analgesic effects seen in its structural relatives. Benzylisoquinoline alkaloids, including papaverine, are biosynthesized via a pathway that starts with two units of the amino acid tyrosine, which are condensed through a series of enzymatic reactions, forming the precursor norcoclaurine. Through further methylation and oxidation steps, papaverine is eventually formed (2).

Figure 1: Chemical structure of PPV



This biosynthetic pathway has been well studied, especially in *Papaver somniferum*, where papaverine, along with morphine and codeine, is produced as part of a complex alkaloid metabolic network (3). Papaverine's biosynthesis involves enzymes such as norcoclaurine synthase and several O-methyltransferases, which catalyze the key steps leading to the formation of its distinct structure (4). Recent advances in molecular genetics have allowed the identification of specific biosynthetic genes responsible for the production of benzylisoquinoline alkaloids, enhancing our understanding of papaverine's synthesis at the molecular level (5).

Sources and Extraction Methods from *Papaver somniferum*

Papaverine is naturally found in the latex of the unripe seed capsules of *Papaver somniferum L.*, commonly known as the opium poppy. This species, which is cultivated primarily in regions such as Afghanistan, Turkey, and Southeast Asia, produces several alkaloids, including papaverine, morphine, and codeine, in varying concentrations depending on the specific variety and environmental factors (6). In *P. somniferum*, papaverine makes up approximately 1–3% of the total alkaloid content, a relatively small proportion compared to morphine, which constitutes about 10–15% (7).

The extraction of papaverine from *Papaver somniferum* involves a series of chemical processes designed to isolate the alkaloid from the plant's latex. Traditional extraction methods involve the use of solvents such as chloroform or ethanol to solubilize the alkaloids, followed by purification techniques like crystallization or column chromatography to separate papaverine from other alkaloids (8). Recent advances in extraction techniques, such as supercritical fluid extraction and molecular distillation, have improved the efficiency and yield of papaverine extraction, making it more feasible for pharmaceutical use (9).

Comparison with Other Benzylisoquinoline Alkaloids

Benzylisoquinoline alkaloids are a diverse class of plant-derived compounds that share a common biosynthetic origin but differ significantly in their pharmacological properties. While morphine and codeine, both derived from *P. somniferum*, are well-known for their potent analgesic effects, papaverine's primary action lies in its ability to inhibit phosphodiesterase and induce smooth muscle relaxation (10). Unlike morphine, which interacts with opioid receptors in the central nervous system, papaverine exerts its effects peripherally, particularly in vascular tissues, without leading to narcotic effects (11).

The pharmacological profiles of these alkaloids reflect their structural variations. For instance, the absence of nitrogen within a cyclic structure in papaverine's molecular architecture prevents it from acting as an opioid receptor agonist, differentiating it from compounds like morphine and thebaine (12). This structural divergence explains why papaverine is used as a vasodilator and antispasmodic, whereas other alkaloids in the same family are employed primarily for their analgesic or antitussive properties (13). The comparison underscores the therapeutic diversity within the benzylisoquinoline alkaloid class, with papaverine representing a non-narcotic therapeutic option among opium-derived compounds (14).

Natural Source of Papaverine

Papaverine is primarily derived from *Papaver somniferum*, commonly known as the opium poppy. This species, which has been cultivated for centuries, is known for its production of several bioactive alkaloids, including morphine, codeine, and thebaine, along with papaverine (12). *P. somniferum* is grown in regions such as Afghanistan, Turkey, and Southeast Asia, where it plays a significant role in both traditional medicine and pharmaceutical applications. While most focus has been placed on the analgesic properties of morphine and codeine, papaverine's unique pharmacological profile as a vasodilator distinguishes it within the opium alkaloid group (13).

In addition to *P. somniferum*, other species within the Papaver genus, such as Papaver bracteatum and Papaver rhoeas, have also been investigated for their alkaloid content. However, papaverine production is largely restricted to *P. somniferum*, where it accounts for approximately 1–3% of the total alkaloid content of the plant's latex (14).

Chemistry of Papaverine

Papaverine is classified as a benzylisoquinoline alkaloid, distinct from the opiates derived from *P. somniferum* due to

its lack of analgesic properties (15). Its chemical structure, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, consists of an isoquinoline core with methoxy substitutions, which contribute to its pharmacological activity as a smooth muscle relaxant (16). This structural difference underpins papaverine's mode of action as a non-narcotic compound, primarily affecting vascular smooth muscle rather than acting on opioid receptors like morphine or codeine (17).

Papaverine's structure was first elucidated in the late 19th century by Guido Goldschmiedt, and its synthesis was later confirmed in 1909 by Pictet and Gams, who demonstrated the compound's vasodilatory properties (18). The compound's unique chemical profile has allowed it to be used in various clinical settings, particularly in the treatment of vasospasms and vascular disorders (19).

Biosynthesis of Papaverine

The biosynthesis of papaverine in *P. somniferum* involves several enzymatic steps, starting with two molecules of tyrosine. The initial reaction converts tyrosine into (S)-norcoclaurine, a common precursor for many benzylisoquinoline alkaloids (20). From there, a series of methylation and hydroxylation steps, mediated by specific enzymes, lead to the formation of papaverine (21).

Two main biosynthetic pathways have been identified for papaverine production in *P. somniferum*: the N-demethylated (NH) pathway and the N-methylated (NCH3) pathway. The NH pathway proceeds through intermediates like norreticuline, while the NCH3 pathway involves (S)-reticuline, which undergoes further methylation to produce laudanine and, ultimately, papaverine (22). The complex nature of these pathways highlights the biochemical diversity of alkaloid production in the opium poppy, and ongoing research continues to unravel the specific genes and enzymes involved in papaverine biosynthesis (23).

Mechanism of Action of Papaverine

Papaverine exerts its pharmacological effects primarily through the inhibition of phosphodiesterase enzymes (PDE), specifically targeting cAMP and cGMP phosphodiesterases in smooth muscle cells (24). This inhibition leads to increased intracellular concentrations of cAMP and cGMP, which subsequently promote smooth muscle relaxation by reducing calcium ion levels and interfering with myosin light-chain kinase (MLCK) activity (25). These effects are particularly pronounced in vascular smooth muscle, making papaverine effective in treating conditions like vasospasms and pulmonary hypertension (26).

Additionally, papaverine has been shown to influence mitochondrial activity by modulating the activity of protein kinase A (PKA) and mitochondrial complex I. This modulation affects cellular metabolism and has been linked to papaverine's potential anticancer properties, as the compound can induce cell cycle arrest and apoptosis in certain tumor cell lines (27).

PHARMACOLOGICAL PROPERTIES OF PAPAVERINE

Cardiovascular Effects

Papaverine's primary clinical use is in the management of vascular disorders due to its potent vasodilatory effects. It is commonly used to treat cerebral and coronary vasospasms, conditions in which blood vessels constrict, reducing blood flow and potentially leading to ischemia (28). Papaverine acts by relaxing the smooth muscles of blood vessels, thereby increasing blood flow and reducing vascular resistance (29).

Pulmonary Vasoconstriction

In addition to its cardiovascular effects, papaverine has shown promise in treating pulmonary vasoconstriction, a condition that often leads to pulmonary hypertension. By relaxing the smooth muscle in the pulmonary arteries, papaverine can lower pulmonary vascular resistance, improving oxygenation and overall pulmonary function (30).

Antiviral and Anticancer Potential

Recent research has explored papaverine's potential beyond its traditional applications. Studies have indicated that papaverine may possess antiviral properties, particularly in inhibiting the replication of certain viruses, including SARS-CoV-2, by interfering with viral RNA synthesis and other critical processes (31). Additionally, papaverine has shown promise as an anticancer agent, with evidence suggesting it can induce apoptosis in tumor cells and inhibit the growth of certain cancer cell lines by disrupting mitochondrial function and cell cycle progression (32).

Pharmacokinetics and Toxicology

Despite its established therapeutic uses, papaverine's pharmacokinetics and toxicity profile require further exploration. Studies have shown that papaverine is metabolized primarily in the liver and excreted via the kidneys, but its long-term safety, particularly with chronic use, remains under-researched (33). Understanding the full pharmacokinetic profile of papaverine is essential to optimizing its therapeutic potential while minimizing potential adverse effects, such as hepatotoxicity or nephrotoxicity (34).

Challenges and Future Directions in Papaverine Research

While papaverine has been widely used for its vasodilatory properties, several challenges remain in fully understanding its broader therapeutic potential. One major limitation is the lack of comprehensive studies on its long-term safety, particularly concerning its effects on mitochondrial function and its potential role in cancer therapy. Future research should focus on elucidating the molecular mechanisms underlying papaverine's diverse pharmacological actions, as well as its potential applications in antiviral therapies, cancer treatment, and neuroprotection (35).

Additionally, advances in biosynthetic pathway engineering could pave the way for increased production of papaverine through biotechnological methods, which may reduce reliance on traditional extraction from *P. somniferum* and allow for more sustainable production methods (36).

CONCLUSIONS

Papaverine, a benzylisoquinoline alkaloid derived primarily from *Papaver somniferum*, has established itself as a significant compound in the field of pharmacology due to its potent vasodilatory effects. While traditionally used to treat vascular conditions such as cerebral and coronary vasospasms, emerging research has uncovered broader pharmacological applications, including potential antiviral, anticancer, and neuroprotective properties. By inhibiting phosphodiesterase enzymes, papaverine elevates intracellular levels of cAMP and cGMP, leading to smooth muscle relaxation and improvements in blood flow.

Recent studies have expanded its therapeutic scope, particularly in addressing pulmonary vasoconstriction and exploring its capacity to modulate mitochondrial function in cancer cells. Additionally, its antiviral potential, demonstrated by its ability to inhibit viral replication, including that of SARS-CoV-2, points to promising new applications for papaverine in viral therapeutics.

Despite these advancements, several challenges remain.

There is a need for comprehensive studies to better understand papaverine's long-term safety, pharmacokinetics, and toxicological profile, especially with chronic use. Future research should also investigate the molecular mechanisms underpinning its anticancer and antiviral effects, as well as its broader therapeutic potential in neuroprotection and disease management.

In conclusion, while papaverine's role as a vasodilator is well established, its full therapeutic potential is far from realized. With further research, particularly into its broader pharmacological activities, papaverine could prove to be a versatile compound with applications far beyond its current clinical use. Continued exploration of its biosynthesis and molecular pathways will also enhance its availability and utilization in modern medicine.

Conflict of Interest: No conflict of interest was declared by the authors
Ethics: Ethics committee permission is not required for this study.
Funding: There is no financial support of any person or institution in this research.
Approval of final manuscript: All authors.

REFERENCES

1. Arora L, Hosn MA. Spinal cord perfusion protection for thoraco-abdominal aortic aneurysm surgery. Curr Opin Anaesthesiol. 2019;32:72–79.
2. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: Current status and new directions. Oncology. 2002;63:2–10.
3. Weiss JF, Landauer MR. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology. 2003;189:1–20.
4. Alam S, Emon N, Shahriar S, Richi F, Haque M, Islam M, et al. Pharmacological and computer-aided studies provide new insights into Millettia peguensis Ali (Fabaceae). Saudi Pharm J. 2020;28:1777–1790.
5. Ashrafi S, Alam S, Emon N, Ahsan M. Isolation, characterization and pharmacological investigations of a new phenolic compound along with four others firstly reported phytochemicals from Glycosmis. Molecules. 2022;27:5972.
6. Amin MN, Emdadul M, Mukul H, Millat MS, Saif M, Rashed U. Phytochemical nature and pharmacological evaluation of chloroform extract of Pandanus fascicularis L. (Fruits): an in vivo study. J Bioanal Biomed. 2017;9:4.
7. Pyne ME, Narcross L, Fossati E, Bourgeois L, Burton E, Gold ND, et al. Reconstituting plant secondary metabolism in Saccharomyces cerevisiae for production of high-value benzylisoquinoline alkaloids. Methods Enzymol. 2016;575:195–224.
8. Ziegler J, Facchini PJ. Alkaloid biosynthesis: metabolism and trafficking. Annu Rev Plant Biol. 2008;59:735–769.
9. Benej M, Hong X, Vibhute S, Scott S, Wu J, Graves E, et al. Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A. 2018;115:10756–10761.
10. Butnariu M, Quispe C, Herrera-Bravo JJ, Pentea M, Sarac I, Küşümler A, et al. Papaver plants: current insights on phytochemical and nutritional composition along with biotechnological applications. Oxid Med Cell Longev. 2022;2022:2041769.
11. Peter KV. Handbook of herbs and spices. Amsterdam: Elsevier; 2012.
12. Shamma M. The Isoquinoline Alkaloids Chemistry and Pharmacology. Amsterdam: Elsevier; 2012.
13. Desgagné-Penix I, Facchini PJ. Systematic silencing of benzylisoquinoline alkaloid biosynthetic genes reveals the major route to papaverine in opium poppy. Plant J. 2012;72:331–344.
14. Yan J, Mi JQ, He JT, Guo ZQ, Zhao MP, Chang WB. Development of an indirect competitive ELISA for the determination of papaverine. Talanta. 2005;66:1005–1011.
15. Han X, Lamshöft M, Grobe N, Ren X, Fist A, Kutchan T, et al. The biosynthesis of papaverine proceeds via (S)-reticuline. Phytochemistry. 2010;71:1305–1312.
16. Gaber A, Alsanie WF, Kumar DN, Refat MS, Saied EM. Novel papaverine metal complexes with potential anticancer activities. Molecules. 2020;25:5447.
17. Srivastava A, Agrawal L, Raj R, Jaidi M, Raj SK, Gupta S, et al. Ageratum enation virus infection induces programmed cell death and alters metabolite biosynthesis in Papaver somniferum. Front Plant Sci. 2017;8:1172.
18. Agarwal P, Pathak S, Kumar RS, Dhar YV, Pandey A, Shukla S, et al. 3′O-methyltransferase, Ps3′OMT, from opium poppy: involvement in papaverine biosynthesis. Plant Cell Rep. 2019;38:1235–1248.
19. Beaudoin GAW, Facchini PJ. Benzylisoquinoline alkaloid biosynthesis in opium poppy. Planta. 2014;240:19–32.
20. Ivanova B, Spiteller M. On the biosynthetic pathway of papaverine via (S)-reticuline—theoretical vs. experimental study. Nat Prod Commun. 2012;7:581–586.
21. Pathak S, Lakhwani D, Gupta P, Mishra BK, Shukla S, Asif MH, et al. Comparative transcriptome analysis using high papaverine mutant of Papaver somniferum reveals pathway and uncharacterized steps of papaverine biosynthesis. PLoS One. 2013;8.
22. Pienkny S, Brandt W, Schmidt J, Kramell R, Ziegler J. Functional characterization of a novel benzylisoquinoline O-methyltransferase suggests its involvement in papaverine biosynthesis in opium poppy (Papaver somniferum L.). Plant J. 2009;60:56–67.
23. Abusnina A, Lugnier C. Therapeutic potentials of natural compounds acting on cyclic nucleotide phosphodiesterase families. Cell Signal. 2017;39:55–65.
24. Debnath B, Singh W, Das M, Goswami S, Singh M, Maiti D, et al. Role of plant alkaloids on human health: a review of biological activities. Mater Today Chem. 2018;9:56–72.
25. Dong HH, Guang YB, Tae KY, Byung SS, Yong GK, Chul JK. The effect of papaverine on ion channels in rat basilar smooth muscle cells. Neurol Res. 2007;29:544–550.
26. Gomes D, Joubert A, Visagie M. In vitro effects of papaverine on cell proliferation, reactive oxygen species, and cell cycle progression in cancer cells. Molecules. 2021;26:6388.
27. Shimizu K, Yoshihara E, Takahashi M, Gotoh K, Orita S, Urakawa N, et al. Mechanism of relaxant response to papaverine on the smooth muscle of non-pregnant rat uterus. J Smooth Muscle Res. 2000;36:83–91.
28. Liu JK, Couldwell WT. Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;2:124–132.
29. Hebb ALO, Robertson HA, Denovan-Wright EM. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. Eur Neuropsychopharmacol. 2008;18:339–363.
30. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology. 2009;203:723–735.
31. Lee YY, Park JS, Leem YH, Park JE, Kim DY, Choi YH, et al. The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models. J Neuroinflammati• Bakr AM, El-Sakka AA, El-Sakka AI. Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2020;22:821–834.
32. Fusi F, Manetti F, Durante M, Sgaragli G, Saponara S. The vasodilator papaverine stimulates L-type Ca2+ current in rat tail artery myocytes via a PKA-dependent mechanism. Vascul Pharmacol. 2016;76:53–61.
33. Berkó S, Zsikó S, Deák G, Gácsi A, Kovács A, Budai-Szűcs M, et al. Papaverine hydrochloride containing nanostructured lyotropic liquid crystal formulation as a potential drug delivery system for the treatment of erectile dysfunction. Drug Des Devel Ther. 2018;12:2923–2931.
34. Bivalacqua TJ, Champion HC, Hellstrom WJG, Kadowitz PJ. Pharmacotherapy for erectile dysfunction. Trends Pharmacol Sci. 2000;21:484–489.
35. Mcmahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust. 2019;210:469–476.
36. Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7:524–540.